• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    This invention relates to a novel influenza vaccine comprising a complex of HANA antigen and an MDP derivative. The novel vaccine is prepared by mixing an influenza HANA antigen and at least one MDP derivative in a suitable medium; solubilizing the resulting mixture with a surface active agent capable of being removed by dialysis, the solubilization being conducted in the presence or absence of cholesterol, lecithin and dicetyl phosphate or a mixture thereof; and then removing the surface active agent therefrom by dialysis to obtain an influenza vaccine comprising artificial vesicle-like particles of a complex of HANA antigen and MDP derivative, where the MDP derivative forms a membrane of the particle (corresponding to the lipid membrane of natural influenza virus particle) on the surface of which there exists the HANA antigen being bonded to the MDP derivative so as to form the complex. Thus, said aritificial vesicle-like particle of the HANA antigen-MDP derivative complex has nearly the same particle size and shape as the natural influenza virus particle. The novel vaccine has an improved immunogenecity compared with the conventional vaccine.
    公开号:SU1651782A3
    申请号:SU864027675
    申请日:1986-06-05
    公开日:1991-05-23
    发明作者:Нероме Куниаки；Оя Акира；Охкума Кунио；Иное Ацуо
    申请人:Нэшнл Институт Оф Хелт (Фирма)；Даити Сеяку Ко., Лтд (Фирма)；Джуридикл Фаундейшн Дзе Кемо-Серотерапеутик Рисерч Институт (Фирма)；
    IPC主号:
    专利说明:

    5 (srav-, suspicious)
    HANA 0.8 µg N -did
    sixteen
    32
    there is
    2, S 10
    Shgamm A () 1/74 for all trains.
    Sample
    Composition, mcg
    6 7
    ten
    HANA 1.0 µg N B30-MDP 30 HANA 1.0 µg N 30 Lecithin 450 Ditsetilphosphate 50 HANA 1.0 µg N B30-MDP 30 Cholesterol 50 HANA 1.0 µg N MDP- (L18) 30 Lecithin 450 Ditsetilphosphate 50 HANA 1.0 µg N MDP- (L18) 30 Cholesterol 50
    1 (compare
    Italic) HANA 1.0 µg N
    table 2
    Ability to form antibodies (HI value) (after 3 weeks)
    512
    512
    1024
    1024
    512
    256
    权利要求:
    Claims (1)
    [1]
    Claim
    A method for producing influenza vaccine, zina, including infection of the chicken embryo virus, production of a virus-containing allantoic fluid, purification of the influenza virus and removal of the hemagglutinin-neutralinidase complex from it, characterized in that, in order to increase the immunogenicity of the target product, hemagglutinin is additionally mixed —Neuraminidase complex in a mass ratio of 1: 1-100 or with a muramyl dipeptide derivative selected from the group of substances of the general formula.
    NON
    NHCOCH
    C0NH,
    I 1 CH 3 Cx-NHCHCH,
    20 1 CH z CO-i / where X is either alanine or serine or
    25 valine, or glycine;
    Y represents NH-A or IL Va
    NHCH (CHg) „- NHCO-A, where A is a saturated or unsaturated, · 301 branched or unbranched residue containing 8-30 carbon atoms, R is hydrogen or alkyl, or a carboxamide or carboxyl group, η = 1- 6, or with a mixture of muramyl dipeptide
    35 derivative with cholesterol in a mass ratio of 2: 1-2, or with a mixture of muramyl dipeptide compounds in a mass ratio of 1: 1-20 with lecithin, or a mixture of lecithin with dicetyl phosphate in a mass ratio of 2-1: 1, followed by dissolution of the resulting mixture with a surface-active a substance selected from the group: octyl glucoside and sodium cholate, and uda-,
    45 by dialysis.
    MN - Acyl
    CH.CHCO-A ~ D- / so ^ / 7
    0 *
    Table 1
    Sample Composition, mcg Faculty of Education - Test resultniya antibodies (significant— infectious protection111)G weeks 2 weeks 3 weeks Availability number air * · virus Research institutes number / ml 1 NALA * 0.3 mcg N <16 64 128 Not 10> B3O-MDP 50 2 NALA 0.8 mcg LB30-MDP 50 Cholesterol 50 64 128 256 Not 10> 3 NALA 0.8 mcg NVZO-MZR 50Lecithin 250 <16 32 64 Not 10> Diethyl Phosphate 250 4 NALA 0.8 mcg LMDP-LYS (L18) 50Lecithin 250 32 64 512 Not 10> Diethyl Phosphate 250 5 (compare.Muscular) NALA 0.8 mcg N j0 16 32 there is .2, s.u ·
    Strain A (Bangkok) 1/74 in all formulations.
    table 2
    Sample
    Composition, mcg
    Ability to form antibodies (H1 value) (after 3 weeks)
    6 HANA * 1.0 mcg N • 512 7 B30-MDP 30 HANA 1.0 mcg NB30-MDP 30 512 θ Lecithin 450 Dicyl Phosphate 50 HANA 1.0 mcg NB30-MDP 30 1024 Cholesterol 50 9 HANA 1.0 mcg NMDP- (L18) 30 1024 10 Lecithin 450Diethyl Phosphate 50 'HANA 1.0 mcg NMDP- (L18) 30 512 Cholesterol 50 11 (comparative) HANA 1.0 mcg N 256
    Strain A (Philippines) 2/82 in all formulations *
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1651782A3|1991-05-23|Method for anti-influenzal vaccine preparation
    CA2017507C|1996-11-12|Adjuvant formulation comprising a submicron oil droplet emulsion
    EP1439184B1|2010-06-16|Immunological adjuvant compounds
    JP5019494B2|2012-09-05|Aqueous immune adjuvant composition of monophosphoryl lipid A
    CN1096851C|2002-12-25|Adjuvant for a vaccine composition
    HU0004147A2|2001-04-28|Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
    EP1649861A2|2006-04-26|Adjuvant compositions comprising a mineral salt and another immunostimulating compound
    EP1420825A2|2004-05-26|Immunomodulatory compounds and methods of use thereof
    US4117113A|1978-09-26|Immunological preparations
    EP0954286A2|1999-11-10|Liposomal influenza vaccine composition and method
    US6261573B1|2001-07-17|Immunoadjuvants
    RU2074192C1|1997-02-27|Muramyldipeptide derivatives, antiinfluenza vaccine
    US20030153532A1|2003-08-14|Immunomodulatory compounds and methods of use thereof
    JP2004505059A|2004-02-19|Immune adjuvant compounds, compositions and methods of use thereof
    GB1564500A|1980-04-10|Biological preparations
    WO1989004314A1|1989-05-18|Anti-viral compounds and compositions containing them
    Thibodeau1991|Immunosome technology to improve antigen presentation for efficient and safe viral vaccines
    JPH0733656A|1995-02-03|Immunopotentiator
    EP0547681A2|1993-06-23|Synthetic peptides comprising a cyclic HIV principal neutralizing determinant and a lipopeptide
    AU2916302A|2002-05-16|Aqueous immunologic adjuvant compositions of monophosphoryl lipid
    同族专利:
    公开号 | 公开日
    CN1020407C|1993-05-05|
    EP0205098A3|1989-03-22|
    EP0205098A2|1986-12-17|
    KR870000075A|1987-02-16|
    AT76756T|1992-06-15|
    DE3685519T2|1993-01-21|
    CN86103717A|1987-02-11|
    AU585353B2|1989-06-15|
    CS419786A2|1989-04-14|
    US4826687A|1989-05-02|
    AU5836586A|1986-12-18|
    CA1262091A|1989-10-03|
    CS269981B2|1990-05-14|
    ES8707113A1|1987-07-01|
    JPH0688911B2|1994-11-09|
    KR940001373B1|1994-02-21|
    JPS61282321A|1986-12-12|
    DE3685519D1|1992-07-09|
    EP0205098B1|1992-06-03|
    ES555748A0|1987-07-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4009258A|1972-09-25|1977-02-22|The Mount Sinai School Of Medicine Of The City University Of New York|Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same|
    CH589453A5|1974-01-14|1977-07-15|Sandoz Ag|
    US4117113A|1974-06-25|1978-09-26|National Research Development Corporation|Immunological preparations|
    US4196191A|1975-09-29|1980-04-01|Burroughs Wellcome Co.|Biological preparations|
    US4261975A|1979-09-19|1981-04-14|Merck & Co., Inc.|Viral liposome particle|
    AT8584T|1980-01-16|1984-08-15|Hans Georg Prof. Dr. Weder|METHOD AND DIALYZER FOR PRODUCING BILAYER VESICLES AND USE OF BILAYER VESICLES.|
    EP0047480B1|1980-09-05|1986-02-05|Institut Armand Frappier|Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane|
    US4327182A|1981-01-22|1982-04-27|Connaught Laboratories Incorporated|Purification of influenza sub-unit vaccine|
    US4565696A|1983-08-03|1986-01-21|The Regents Of The University Of California|Production of immunogens by antigen conjugation to liposomes|
    FR2551758B1|1983-08-16|1986-01-31|Anvar|MURAMYL-PEPTIDES AND STEROID DERIVATIVES HAVING MACROPHAGE ACTIVATION PROPERTIES|
    IL69720A|1983-09-14|1987-08-31|Univ Ramot|Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins|
    US4663161A|1985-04-22|1987-05-05|Mannino Raphael J|Liposome methods and compositions|US6090406A|1984-04-12|2000-07-18|The Liposome Company, Inc.|Potentiation of immune responses with liposomal adjuvants|
    US5897873A|1984-04-12|1999-04-27|The Liposome Company, Inc.|Affinity associated vaccine|
    US5916588A|1984-04-12|1999-06-29|The Liposome Company, Inc.|Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use|
    US5026557A|1987-09-09|1991-06-25|The Liposome Company, Inc.|Adjuvant composition|
    WO1990001947A1|1988-08-25|1990-03-08|The Liposome Company, Inc.|Affinity associated vaccine|
    JPH04500203A|1988-08-25|1992-01-16|
    US5100662A|1989-08-23|1992-03-31|The Liposome Company, Inc.|Steroidal liposomes exhibiting enhanced stability|
    WO1991011174A1|1990-01-25|1991-08-08|The University Of Colorado Foundation, Inc.|Method for preventing immune suppression in trauma patients|
    JP2777258B2|1990-03-13|1998-07-16|第一製薬株式会社|Muramyl dipeptide-containing lipid membrane structure|
    US5091188A|1990-04-26|1992-02-25|Haynes Duncan H|Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs|
    US5246707A|1990-04-26|1993-09-21|Haynes Duncan H|Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes|
    GB9018690D0|1990-08-24|1990-10-10|Wellcome Found|Vaccines|
    IL99851A|1990-10-30|1996-06-18|Daiichi Seiyaku Co|Muramyldipeptide derivatives and influenza vaccine containing them|
    AT280585T|1994-02-24|2004-11-15|Micro Pak Inc|Vaccines that contain paucilamellar lipid vesicles as adjuvants|
    AT386506T|1995-10-17|2008-03-15|Jagotec Ag|ADMINISTRATION OF UNSUCCESSFUL MEDICINAL PRODUCTS|
    US7255877B2|1996-08-22|2007-08-14|Jagotec Ag|Fenofibrate microparticles|
    US6465016B2|1996-08-22|2002-10-15|Research Triangle Pharmaceuticals|Cyclosporiine particles|
    WO1999040906A2|1998-02-11|1999-08-19|Research Triangle Pharmaceuticals|Method and composition for treatment of inflammatory conditions|
    US6979456B1|1998-04-01|2005-12-27|Jagotec Ag|Anticancer compositions|
    WO1999061001A1|1998-05-29|1999-12-02|Rtp Pharma Inc.|Thermoprotected microparticle compositions and process for terminal steam sterilization thereof|
    AT252889T|1998-08-19|2003-11-15|Skyepharma Canada Inc|INJECTABLE AQUEOUS PROPOFOL DISPERSIONS|
    IL143197D0|1998-11-20|2002-04-21|Rtp Pharma Inc|Dispersible phospholipid stabilized microparticles|
    EP1214059B1|1999-09-21|2005-05-25|Skyepharma Canada Inc.|Surface modified particulate compositions of biologically active substances|
    MXPA03011611A|2001-06-29|2004-07-01|Becton Dickinson Co|Intradermal delivery of vaccines and gene therapeutic agents via microcannula.|
    CN1313080C|2000-04-20|2007-05-02|斯凯伊药品加拿大公司|Improved water-insoluble drug particle process|
    ES2325057T3|2000-08-31|2009-08-25|Jagotec Ag|MOLDED PARTICLES.|
    WO2002024193A1|2000-09-20|2002-03-28|Skyepharma Canada Inc.|Stabilised fibrate microparticles|
    US8586094B2|2000-09-20|2013-11-19|Jagotec Ag|Coated tablets|
    JP2004523552A|2001-02-22|2004-08-05|スカイファーマ・カナダ・インコーポレーテッド|Fibrate-statin combination with reduced feeding-fasting effect|
    WO2002074336A2|2001-02-23|2002-09-26|Glaxosmithkline Biologicals S.A.|Influenza vaccine formulations for intradermal delivery|
    US20060058736A1|2001-04-27|2006-03-16|Alchas Paul G|Novel vaccine|
    JP2006522022A|2003-02-14|2006-09-28|ザキュレイターズオブザユニバーシティーオブミズーリ|Contraceptive methods and compositions associated with proteasome interference|
    US7588774B2|2003-05-12|2009-09-15|Becton, Dickinson And Company|Molecules enhancing dermal delivery of influenza vaccines|
    US20050123550A1|2003-05-12|2005-06-09|Laurent Philippe E.|Molecules enhancing dermal delivery of influenza vaccines|
    AR056245A1|2003-06-19|2007-10-03|Bestewil Holding Bv|FUNCTIONAL RECONSTITUTED VIRAL MEMBRANES CONTAINING A COADYUVANT|
    WO2005074460A2|2003-12-05|2005-08-18|Becton Dickinson And Company|Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods|
    US20060121055A1|2004-12-06|2006-06-08|Becton, Dickinson And Company, Inc.|Compositions with enhanced immunogenicity|
    US7468187B2|2005-10-18|2008-12-23|Iowa State University Research Foundation, Inc.|Canine influenza virus and related compositions and methods of use|
    EP2139908A4|2007-03-12|2011-02-16|Antigen Express Inc|Li-rnai involved li suppression in cancer immunotherapy|
    WO2009131995A1|2008-04-21|2009-10-29|Nanobio Corporation|Nanoemulsion influenza vaccine|
    JP2014520805A|2011-07-06|2014-08-25|ナノバイオコーポレーション|Human respiratory syncytial virus vaccine|
    JP6205360B2|2011-08-22|2017-09-27|ナノバイオ コーポレーション|Herpes simplex virus nanoemulsion vaccine|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP60123341A|JPH0688911B2|1985-06-06|1985-06-06|Influenza vaccine and method for producing the same|
    [返回顶部]